🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07235254
Starting soon Not applicable

A RCT of Moist Ag Dressing in Chronic Wound

NCT07235254 · tracked via the Priya Life Science China tracker
Sponsor
Peking University Third Hospital
Phase
Not applicable
Started
2025-12-01
Last updated
2025-11-19

Condition(s) studied

Chronic WoundHard to Heal WoundsDressingWound he'a'LingWound Healing

Investigational drug(s) / intervention(s)

Ag foam dressing named MepilexAgDry Ag dressing

Ag foam dressing named MepilexAg: Using MepilexAg in conjunction with conventional clinical treatments in chronic local infectious ulcer

Dry Ag dressing: Using dry Ag dressing in conjunction with conventional clinical treatments

Study summary

This study aims to explore the differences in efficacy and cost-effectiveness between self-adhesive soft polysilicone silver ion foam dressings and traditional silver dressings in local infected wounds through a prospective randomized controlled study. The goal is to provide evidence-based medical support for clinical application, further shorten the wound healing time, and reduce the economic burden on the medical system and patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. The patient's age ranges from 18 to 80 years old. 2. According to the IWII wound infection staging, infected wounds are classified as local infections\*. 3. The wound type is ulcer, with an ulcer area ranging from 1 to 40 cm². 4. The wound stage is in the necrosis stabilization phase, granulation growth phase, or epithelial crawling phase\*\*. 5. Voluntary participation in this study and signing the informed consent form Exclusion Criteria: 1. Severe diseases such as acute myocardial infarction, heart failure, hepatitis, shock, and respiratory failure have not been corrected yet; 2. The blood sugar level of diabetes is out of control, with fasting blood sugar \> 15 mmol/L and glycosylated hemoglobin ≥ 10%; 3. There is active bleeding in the wound, and the conventional basic treatment plan cannot be implemented; 4. Serum albumin \< 20 g/L; hemoglobin \< 60 g/L; platelets \< 50 × 109/L; 5. Disseminated infection or systemic infection state, and antibiotics are being used or will be used for treatment; 6. Patients with advanced malignant tumors; 7. The patient is in the active stage of autoimmune diseases; 8. The patient has previously been allergic to self-adhesive soft polysilicone silver ion foam dressings (Meipikang Silver) or Anxidean Nano Silver Trauma Patch; 9. The patient cannot cooperate or has a mental disorder; 10. According to the investigator's judgment, the subject has clear reasons that affect wound healing and is not suitable for this study or cannot comply with the requirements of this study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Peking University Third Hospital Beijing Beijing Municipality

More Peking University Third Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07235254 on ClinicalTrials.gov ↗ ← All trials in China